Background: Vitamin A is a potent regulator of adaptive immunity. The effect of the endogenous metabolite 9-cis retinoic acid (9cRA) on allergic sensitization is unknown. Objective: We sought to investigate whether and to what extent 9cRA modulates the humoral immune response.
absence of 9cRA and activation markers, and proliferation and secreted immunoglobulin levels were analyzed by using flow cytometry and ELISA. Results: 9cRA applied together with repeated OVA challenge transiently increased specific serum IgA, IgE, and IgG 1 serum levels (2.0-and 8.9-fold). After OVA recall, specific IgE concentrations were reduced by a mean of 57% after adding 9cRA, whereas IgA was strongly induced (20-fold) , and IgG 1 levels remained unchanged. Correspondingly, less specific IgE-and more IgA-secreting cells resided in the spleen in the 9cRA groups. Additionally, 9cRA promoted the migration of specific B cells to the mesenteric but not draining lymph nodes. In purified stimulated human B cells, 9cRA markedly reduced IgE production and enhanced IgA production. B-cell activation was modulated by 9cRA, reducing the expression of CD86 and promoting IL-10. Conclusions: Our data indicate that 9cRA modulates the allergic immune response by reducing the IgE response but promoting the IgA response. Thus 9cRA can modulate the allergic immune response toward a non-IgE condition. (J Allergy Clin Immunol 2018;141:650-8.)
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The adaptive immune response is shaped by environmental factors, including vitamin A. 1, 2 This effect on the protective immune response prompted the World Health Organization to recommend vitamin A treatment in conjunction with vaccination against measles, tetanus, or polio in developing countries. 3, 4 Analysis of vitamin A-deficient mice confirms an abrogated specific IgG 1/3 humoral immune response after vaccination or infection, which is effectively restored by vitamin A repletion or the active metabolite retinoic acid (RA). [4] [5] [6] The underlying mechanisms include defective T-cell function, reduced B-cell proliferation, and differentiation during primary and memory antibody response. 4, 7 Moreover, vitamin A was shown to facilitate the physiologic IgA response under homeostatic conditions 8 but also during infection 9 and immunization. 10 Human B cells can be directly targeted by the active vitamin A metabolite all-trans retinoic acid (ATRA), which enhances Toll-like receptor 9-induced proliferation and differentiation into IgG-secreting cells. 11 However, the function of vitamin A in allergy is not clear. We previously demonstrated in human B cells that IgE production is inhibited by impaired IgE germline transcript expression and blocked IL-6 production when activated in the presence of ATRA. 12, 13 At the molecular level, vitamin A operates in its active forms through activation of retinoic acid receptors (RARs) and retinoid X receptors (RXRs) and transcriptional regulation of target genes. 14 The diversity of vitamin A functions results from cellspecific expression of vitamin A receptor, its activating metabolite, and also transcriptional cofactors.
14 Human B cells express RARa, RARb, and RXRa.
12,15 9-Cis retinoic acid (9cRA) is a naturally occurring bioactive vitamin A metabolite, which is formed by spontaneous isomerization of ATRA.
14 In addition to targeting RARa-g, like ATRA, 9cRA also activates RXRa-g. 14 Currently, 9cRA is used for the treatment of chronic therapyresistant hand eczema (alitretinoin). Our previous data show that different RXRa partner receptors modulate B-cell activation, including vitamin D receptor, [16] [17] [18] [19] RARa, 12, 13 liver X receptor, 20 and peroxisome proliferator-activated receptor g. 21 However, the effect of 9cRA on B cells and the allergic immune response is not known.
METHODS

Animals and treatments
All animal procedures complied with German institutional, state, and federal guidelines (LaGeSo Berlin). Female BALB/c mice (strain cByJRj; Elevage Janvier, Le Genest St Isle, France) were kept free of specific pathogens and treated as described previously. 22 Briefly, the mice were sensitized intraperitoneally with 10 mg of ovalbumin (OVA) absorbed to alum (Fig 1, A) . When the sensitization-induced plasmablast response decreased, 23 100 mg of OVA administered subcutaneously was applied in weekly intervals with or without 9cRA (dissolved in 10% dimethyl sulfoxide and 20% Tween80 in 0.9% NaCl; Basilea, Basel, Switzerland) to target specific lymphocytes with 9cRA, starting on day 56. Control mice received PBS/solvents accordingly. Doses of 0.43 and 2.43 mg/kg 9cRA in mice correspond to the human treatment daily dose of 3 and 30 mg considering the body surface area. 24 Finally, specific memory B cells were challenged by means of intraperitoneal injection with 100 mg of OVA after allergen-free intervals of 4 to 5 weeks on day 109.
Cell culture
All procedures were approved by the local ethics committee and conducted in accordance with the Declaration of Helsinki. After written informed consent was obtained, CD19
1 B cells were isolated from PBMCs of healthy donors by means of magnetic cell sorting (Miltenyi Biotec, Bergisch Gladbach, Germany) and cultured, as previously described. 18 
Flow cytometry
For flow cytometry, murine B cells were stained after Fcg receptor blockade (clone 2.4G2) by using fluorescently labeled antibodies against B220 (clone RA3.6B2), CD38 (clone 90; BioLegend, San Diego, Calif), CD138 (clone 281-2; BD PharMingen, San Jose, Calif), 7-aminoactinomycin D (7-AAD; eBioscience, San Diego, Calif), CCR9-phycoerythrin (R&D Systems), and anti-a4b7 (clone DATK32; DRFZ, Berlin, Germany). For plasma cell analysis, the cells were additionally fixed in 1% paraformaldehyde, permeabilized in 0.5% saponin/PBS and stained intracellularly with OVA-fluorescein isothiocyanate (Sigma) and IgG 1 -allophycocyanin (clone X56, BD PharMingen). Human B cells were stained with fluorescence-conjugated antibodies against IgD, CD23, CD54, CD86, CD38, IgD, CCR9 (all from BD PharMingen), CD27 (Miltenyi Biotec), and 7-AAD (eBioscience). B-cell proliferation was analyzed after labeling with carboxyfluorescein diacetate succinimidyl ester (CFSE; Sigma) before activation, as previously described. 18, 20 Cells were cultured for 3 to 10 days, as indicated, including a medium change for immunoglobulin cultures on day 3 (measurement intervals were determined previously based on optimal expression levels, data not shown). 13, 16 All flow cytometric analyses were performed with a MACSQuant Analyzer (Miltenyi Biotec) and FlowJo software (Tree Star, Ashland, Ore).
Detection of IL-10 expression in human B cells
Human viable B cells were stained for IL-10 secretion by using the IL-10 capture assay (Miltenyi Biotec), as previously described. 25 Briefly, activated B cells were activated for 4 days at 1.5 3 10 6 cells/mL, as indicated, after restimulation with phorbol 12-myristate 13-acetate (PMA; 10 ng/mL) and ionomycin (1 mg/ml, both from Sigma Aldrich) for 2.5 hours. Harvested 
ELISA and ELISpot
Murine immunoglobulin serum concentrations and ELISpot assay results were determined, as described in detail previously. 20, 26 OVA-specific immunoglobulin levels were obtained by means of serial dilution of a highly positive serum pool and 4-point analysis calculating relative laboratory units. Human IgM, IgA, IgG, and IgE ELISAs were analyzed from cell-free supernatants after 10 days of cell culture, as described previously. 16 Human IL-10 protein levels were determined from cell-free supernatants, according to the manufacturer's instructions (DuoSet, R&D Systems).
Statistical analysis
Statistical analyses and graphic presentation were performed with GraphPad Prism software (GraphPad Software, La Jolla, Calif), with values depicted as means 6 SEMs. Comparisons between 2 groups were determined by using the Mann-Whitney U test or Student t test. Statistical significance was considered at a P value of .05 or less.
RESULTS
9cRA promotes specific IgA and reduces the IgE allergic immune response OVA-sensitized BALB/c mice were challenged 3 times with OVA in weekly intervals, as previously described, 22 in the presence or absence of increasing doses of 9cRA to investigate the effect of 9cRA on the allergic immune response. Reactivation of OVA-specific memory cells (OVA recall) was performed 6 weeks after challenge and 1 week before organ analysis of the mice by administering OVA intraperitoneally (Fig 1, A) . Before sensitization, OVA-specific antibodies were less than the detection threshold. Sensitization induced mainly OVA-specific IgE and IgG 1 in all groups (Fig 1, B-D) . By using repetitive OVA challenges starting at day 56, the addition of 9cRA increased all specific isotypes in the 30-mg 9cRA group compared with the control group (OVA-specific IgA, P < .0001; OVA-specific IgE, P 5 .06; OVA-specific IgG 1 , P 5 .008; Fig 1, B-D) , as well as total IgA levels at a P value of less than .01 and IgE levels at a P value of less than .05 (see Fig E1 in this article's Online repository at www.jacionline.org). Interestingly, 6 weeks after challenge, OVA-specific IgA levels remained higher in the 30-mg 9cRA group (P < .001; Fig 1, B) and OVA-specific IgE levels decreased to values less than control values (P < .01; Fig 1, C) , respectively. Challenging the specific memory immune response at day 109 (OVA recall) showed within 1 week an induction of OVAspecific IgA by 9cRA, resulting in 20-fold higher concentrations (P < .001, 1600-fold intergroup difference; Fig 1, B) . OVAspecific IgE levels remained stable and still lower than in control mice (P < .01; Fig 1, C) , but total IgE levels were induced compared with control values (see Fig E1, B) . OVA-specific IgG 1 , total IgA, and total IgG 1 memory responses were not significantly affected by 9cRA after recall (Fig 1 and see Fig E1) .
Increased numbers of specific IgA-secreting cells caused by 9cRA
ELISpot analyses were performed on day 115 from spleen and bone marrow, the 2 major accumulation sites of antibodysecreting cells in this model, to further elucidate whether the observed changes in specific immunoglobulin serum concentrations by 9cRA were induced by altered differentiation of immunoglobulin-secreting cells, homing, or both (Fig 2) . The total number of splenocytes and bone marrow cells did not differ (Fig 1, B) , IgE (Fig 1, C) , and IgG 1 (Fig 1, D) were determined after sensitization on day 51, after challenges on day 77 (open bars, without 9cRA; orange bars, 3 mg/kg 9cRA; red bars, 30 mg of 9cRA), and before and after OVA recall on days 109 and 116, respectively. Data are shown as means 1 SEMs (n 5 6). *P < _ .05, **P < _ .01, and ***P < _ .001.
between the groups (P 5.73-.34, data not shown). However, in the spleen frequencies of OVA-specific IgA-secreting cells were increased in the presence of 9cRA in a dose-dependent manner compared with control values (P 5 .015, Fig 2) and robustly decreased regarding OVA-specific IgE (P 5 .052) and OVAspecific IgG 1 (P < .01) levels at the 30-mg dose. In bone marrow the presence of 9cRA reduced the numbers of OVA-specific IgG 1 -secreting cells marginally, and the other isotypes were comparable among the groups. Accordingly, absolute numbers of OVA-specific IgA-secreting cells were increased in the presence of 30 mg of 9cRA compared with those in the control group in the spleen and bone marrow (P 5 .015 and .013), whereas those regarding OVA-specific IgG 1 were reduced in the spleen (P 5 .015, both data not shown). Finally, OVA-specific IgG 1 and IgE cell numbers in bone marrow were reduced, although statistical significance was not reached (P > .05, data not shown).
OVA-specific B cells and plasmablasts migrate toward the intestine by using 9cRA
Because 9cRA modulated the presence of specific IgA-and IgE-secreting cell numbers in the spleen, we addressed the question of whether specific B cells are altered in their homing to lymphoid tissue. Therefore OVA-specific memory B cells (B220
1
CD138
2 small lymphocytes) and plasmablasts (CD138
1
B220
-lymphoblasts) were analyzed by means of flow cytometry from the bone marrow, spleen, and lymph nodes (Fig  3, gating strategy 1 1 cells, which are also induced by IL-4. On day 115, the frequencies of OVA-specific IgG 1 memory B cells and plasmablasts were reduced by 9cRA in the spleen in the 30-mg 9cRA group (P 5 .051 and P > .05, respectively, data not shown). Moreover, the data show a reduced presence within the axillar and inguinal lymph nodes but an increased presence in the mesenteric lymph nodes (Fig 3, B) , whereby statistical calculation was limited because of only 2 samples. We detected, in line with OVA-specific IgA induction in the blood, IgG 1 2 OVA-specific B cells in the mesenteric lymph nodes, which are most likely of the IgA isotype, because OVA IgE cells are very rare and not induced by OVA challenge (Fig 1, C) .
B Fig E3, A) but not on plasmablasts. In mice with 9cRA treatment, more CCR9 1 mesenteric IgG 1 2 B cells were detectable. Cell numbers of a4b7 1 B cells were comparable in the spleen in all 3 study groups (data not shown). However, in the mesenteric lymph nodes higher frequencies of all 3 B-cell subsets were observed with an increasing dose of 9cRA (see Fig E3, B) . These data indicate that 9cRA mediated expression of gut-homing surface molecules in a T H 2-mediated immune response, namely CCR9 on B cells and a4b7 on plasmablasts.
9cRA inhibits anti-CD40-and IL-4-induced IgE production in human B cells
Because our data show an impaired IgE response by 9cRA in a murine type I sensitization model and in 9cRA-treated patients with increased serum IgE levels, 27 we investigated its effect on IgE production by human B cells. After anti-CD40 plus IL-4 stimulation of B cells, IgE concentrations were strongly induced (24.4-fold), although IgM, IgG, and IgA concentrations were not (Fig 4, A) . The addition of 9cRA inhibited IgE production significantly (267% 6 8.5%, P < .01), whereas secreted IgM levels were moderately increased (126% 6 52%, P < .05), and IgG/IgA secretion remained stable (P > .05; Fig 4, A) . The comparison of CD27 2 naive and CD27 1 memory B cells sorted before cell culture showed no significant differences between both subsets regarding survival, proliferation, and immunoglobulin secretion (data not shown). Of note, IgA was induced by neither the culture conditions nor 9cRA. To investigate whether IgA-inducing conditions are required to facilitate the enhancing action of 9cRA observed in mice (Fig 1, B) , we activated naive human B cells in the presence of IL-21 and BCR cross-linking F(ab2)9 fragments in addition to CD40 and IL-4 receptor stimulation to mimic physiologic B-cell activation in the lymph nodes with follicular helper T cells. Under these conditions, secreted IgA was significantly induced by the stimulation (mean, 60 ng/ mL in unstimulated cells, not detectable, data not shown). Additional 9cRA further increased IgA production up to a mean of 7.4- Fig 1, and immunoglobulin-secreting cells were analyzed on day 115 by using an OVA-specific ELISpot regarding IgA (A), IgE (B), and IgG 1 (C) isotype. The left column depicts data from the spleen, and the right column depicts data from the bone marrow. The line indicates the mean value (n 5 5-6). *P < _ .05 and **P < _ .01, MannWhitney U test compared with control values.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 2 fold (Fig 4, B) . IgM and IgG secretion was also induced by stimulation containing IL-21 to a mean of 110 ng/mL and 206 ng/mL, which was further increased by 9cRA (mean, 9-and 3-fold), respectively, whereas IgE was not significantly affected (mean, 1.3 ng/mL; P 5 .14).
Flow cytometric analysis of 7-AAD-stained cells and CFSE dilution was analyzed in cultured B lymphocytes to exclude a bias by potential reduced proliferation or viability by 9cRA. The data showed that the viability remained unchanged by 9cRA after stimulation (P > .05, data not shown). Analysis of CFSE-labeled B cells showed induced proliferation by anti-CD40 plus IL-4 (12-fold compared with unstimulated cells), which was reduced by trend in the presence of 9cRA by 49% 6 10% (P 5 .09, data not shown). Fig 1, A. OVA-specific B cells and plasmablasts were analyzed on day 115 by using flow cytometry. Dot plots were gated on live single cells (see Fig E2) . Data are shown as dot plots from 1 representative experiment (A), and as means 1 SEMs from different lymphatic tissues (B; n 5 5-6 mice). Cells from lymph nodes were pooled from 3 individual mice, Mann-Whitney U test compared with control values. nd, Not detectable.
9cRA targets human B cells directly and modulates their activation
To assess which and how human B-cell populations are targeted by 9cRA, we determined the surface expression of the vitamin A-inducible protein CD38 on B cells as a surrogate marker for retinoid signaling (see Fig E4 in this article' s Online repository at www.jacionline.org) 15 and cytokine production, which are crucial for immunoglobulin production in an autocrine manner. 17 Kinetic studies identified day 4 as an optimal time point (data not shown). The data show increased surface CD38 expression on anti-CD40 plus IL-4 and anti-CD40 plus IL-4 plus anti-BCR plus IL-21 activated B cells (see Fig E4, A) .
To assess how 9cRA affects B-cell activation, we first determined the expression of IgE receptor II (CD23) and the costimulatory molecules CD54 (intercellular adhesion molecule 1) and CD86 on B cells. Kinetic studies identified day 3 as an optimal time point (data not shown) for further analysis. In anti- CD40 plus IL-4-stimulated cells, additional 9cRA did not alter CD23 and CD54 expression, but CD86 expression on B cells was significantly reduced by 9cRA (mean, 2-fold; Fig 5, A) . However, unlike in murine B cells CCR9 surface expression was not altered in the presence of 9cRA on human B cells (data not shown). Next, we examined whether 9cRA controls B-cell cytokines involved in differentiation to IgE-secreting cells, namely IL-10 promoting plasmablast differentiation. 25 We determined the secretion of IL-10, considering the kinetics of cytokine expression, as reported previously. 17, 25 After 3 days, IL-10 was induced in B cells by means of stimulation with anti-CD40 plus IL-4. We detected more IL-10 in the supernatants of anti-CD40 plus IL-4-stimulated B cells in the presence of 9cRA, as validated also in conditions including IL-21 and anti-BCR. To clarify, whether this results from a higher frequency of IL-10-secreting cells or more secretion per cell, we performed flow cytometric analysis. We analyzed B cells activated according to established conditions to induce IgA in vitro, including IL-21 plus anti-BCR, because the frequencies of IL-10 1 B cells and amounts of secreted IL-10 were low in response to anti-CD40 plus IL-4 stimulation. 25 The data show significant induction of IL-10-secreting cells by stimulation (mean, 2.8% 6 0.6%), which is increased by 9cRA (mean, 3.3% 6 1.1%; data not shown and see Fig E5 in this article' s Online repository at www.jacionline.org).
DISCUSSION
We have provided evidence that exogenous 9cRA in the context of allergic sensitization profoundly modulates an established humoral IgE response, resulting in reduced specific IgE responses and increased specific IgA responses in mice. Data from human in vitro studies underline that 9cRA directly targets activated human B cells and decreases IgE production.
Our data suggest a novel mechanism in patients with type 1 allergy to control IgE levels through a strong modulatory action of 9cRA on allergen-specific IgA. Generation of an IgA 1 allergenspecific memory B-cell pool irreversibly limits the regeneration of IgE memory B cells because the gene encoding for IgE and IgG subclasses is excised during the process of isotype classswitch recombination to IgA. 28 We demonstrated 9cRA-driven plasmablast generation (early 9cRA function) and polarization of specific memory B cells (late 9cRA function) toward IgA instead of IgE/IgG 1 . Accordingly, serum OVA-specific IgA levels rapidly increased in the 9cRA groups on day 115 after OVA recall (day 109), whereas OVA-specific IgE concentrations and numbers of specific immunoglobulin-secreting cells were unaffected. However, data from human studies indicate that IgA levels remained stable under 9cRA treatment in hand eczema 27 but also in CD40 plus IL-4-activated B cells in vitro, as shown in this study. By simulating B-cell activation in the lymph nodes with additional BCR activation and IL-21, IgA production increased by a factor of up to 7.4 because of 9cRA. These findings suggest that a temporospatial presence of antigens with 9cRA in a specific microenvironment, such as the gut, 8 is required to achieve IgA polarization. Our data from the murine allergic sensitization model using 9cRA confirms a gut tropism of B cells activated in the presence of vitamin A. This was reflected by the increased presence of CCR9
1 B cells and integrin a4b7 1 plasmablasts in mesenteric , and CD86 mean fluorescence intensity (MFI) was analyzed by using flow cytometry. IL-10 concentrations were detected by using ELISA. Mean IL-10 concentrations in the stimulated control group were 16 pg/mL (Fig 5, B) and 1367 pg/mL (Fig 5, C) . Fig 5, A, Exemplary histograms are gated on live B cells (gray shading, stimulated; black line, stimulated plus 9cRA). Bars are normalized to stimulated control and represent means 1 SEMs (n 5 4). *P < .05.
lymph nodes rather than draining lymph nodes. In this respect our study extends the findings of previous reports. 29 We also detected a large proportion of IgG 1 2 B cells and plasmablasts in the mesenteric lymph nodes in the 9cRA groups. These were most likely IgA isotype cells, and their number was dependent on the dose of 9cRA administered.
Whether the induction of gut-homing molecules by 9cRA occurs directly in B cells or indirectly through specialized gutderived dendritic cells that were in contact with vitamin A 2 is as yet unknown. However, the latter option is supported by our finding that these homing receptors were not induced by 9cRA in purified human B cells.
It is still not clear how 9cRA induced IgA in vivo. TGF-b is essential for induction of IgA 28 because IgA is absent in mice with a B cell-specific deletion of the TGF-b receptor. 30 There is still no conclusive evidence whether RA can substitute for TGF-b in the induction of IgA. 31 However, autocrine TGF-b induces IgA switching 32 and is known to be induced by RA. 33 Therefore an indirect mechanism that causes 9cRA to induce IgA in B cells seems probable. Alternatively, RA-induced TGF-b from other cell types, such as intestinal dendritic cells 34 or epithelial cells, 28 and contact with IL-21-secreting follicular helper T cells 35 can serve as indirect mechanisms causing IgA to be produced in B cells. The latter hypothesis is supported by our finding that in vitro anti-CD40 plus IL-4-activated human B cells only secrete IgA in the presence of 9cRA when additionally stimulated with BCR and IL-21.
In addition to its effect on specific IgA induction, our data are of great importance for understanding how established IgE responses are regulated by endogenous and exogenous cofactors because 9cRA is synthesized from vitamin A enzymatically 14 but is also used systemically for chronic inflammatory dermatologic conditions (alitretinoin). Our observation that 9cRA inhibits IgE production in isolated human B cells is in line with reduced serum IgE concentrations in 9cRA-treated patients, 27 suggesting that B cells can be targeted directly. Significantly, the concentrations of 9cRA used in this study were adjusted to levels used during systemic treatment. In addition, our data improve the understanding of 9cRA, building on insights previously gained from the isomer ATRA, which inhibits IgE production in purified human or murine B cells and sensitized mice. 13, 36, 37 In human B cells 9cRA promoted IL-10, as previously demonstrated for ATRA. [11] [12] [13] Flow cytometric analysis showed that 9cRA increases IL-10 expression by increasing the frequencies of producing cells similar to vitamin D. 17 Surface CD86 expression decreased as a result of 9cRA, as well as ATRA, 38, 39 suggesting a common mode of action, namely through RARs and RXRs.
However, the fact that B-cell viability remained unaffected and the beneficial safety and tolerability profile of 9cRA 40 suggest superiority over other retinoids, such as ATRA. B cell-derived IL-10 negatively controls IgE expression, 41 which supports the findings of a recent study that 9cRA-induced IL-10 from B cells contributes to the control of serum IgE levels. 27 However, further detailed studies are required to validate this hypothesis. It would be particularly relevant to analyze the lamina propria, Peyer patches, and B-cell phenotypes in the mesenteric lymph nodes to further understand the mechanism of action of 9cRA.
To sum up, 9cRA targets the humoral immune response in an allergic sensitization model by promoting a specific IgA response and decreasing the IgE response. Our findings indicate that RXRactivating retinoids play a major role in the physiologic regulation of IgE because of the endogenous synthesis of 9cRA. Further research is necessary to clarify whether a specific allergic response can be biased in a long-term manner toward IgA by 9cRA. 
